Drug Type Small molecule drug |
Synonyms PF 6263276, PF-06263276 |
Target |
Mechanism JAK inhibitors(Janus kinase inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC31H31FN8O2 |
InChIKeyXDJGNPSZQSWJCV-UHFFFAOYSA-N |
CAS Registry1421502-62-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Psoriasis vulgaris | Phase 1 | DE | 01 Sep 2014 | |
Plaque psoriasis | Phase 1 | BE | 01 Nov 2013 | |
Dermatitis | Preclinical | US | 04 Jan 2017 | |
Pneumonia | Preclinical | US | 04 Jan 2017 |
Phase 1 | 15 | (PF-06263276 4% Solution) | owktfsopec(ncsyennsme) = lgqiyrbjwi hkhzdctsjq (vkegvsfnqc, iaetxxgauq - olqxbucvka) View more | - | 09 Jun 2016 | ||
(PF-06263276 Vehicle) | owktfsopec(ncsyennsme) = nntojqggii hkhzdctsjq (vkegvsfnqc, ieikpnbesq - wetcdnwkel) View more |